Trump Administration Takes Small Step Toward Justice by Reclassifying Medical Marijuana
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Justice Department has finally reclassified state-licensed medical marijuana from Schedule I to Schedule III, a long-overdue acknowledgment of its medical value and a modest reduction in regulatory barriers.
On Thursday, the Justice Department announced the reclassification of state-licensed medical marijuana from the draconian Schedule I to Schedule III under the Controlled Substances Act. This long-awaited change finally recognizes the legitimate medical use of cannabis, a move activists and patients have demanded for decades, and begins to chip away at the oppressive regulatory system that has stifled research and denied people access to essential medicine. Businesses will now be able to claim tax deductions, a basic right previously denied due to outdated prohibitionist policies.
Acting Attorney General Todd Blanche claimed, "The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options." However, this incremental reform comes after years of inaction and only under mounting public pressure.
Importantly, the reclassification does not legalize marijuana at the federal level, maintaining the status quo of criminalization for millions. It merely follows President Trump’s December executive order, which directed the Justice Department to speed up the process. The administration has announced plans for further reclassification, but these efforts remain limited, with broader hearings not scheduled until June.
Predictably, prohibitionist voices like Kevin Sabet of Smart Approaches to Marijuana have criticized the move, arguing that tax relief only benefits large cannabis corporations and that it sends 'mixed messages' about the drug’s risks. Yet, supporters rightly celebrate this as the most significant—if still insufficient—federal step toward cannabis justice in decades.